相似文献
1
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19.
Pharmacol Res Perspect. 2023 Apr;11(2):e01083. doi: 10.1002/prp2.1083.
2
A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure.
Hypertens Res. 2013 Nov;36(11):959-66. doi: 10.1038/hr.2013.78. Epub 2013 Aug 15.
3
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
J Hum Hypertens. 1999 Oct;13(10):657-64. doi: 10.1038/sj.jhh.1000925.
4
Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
Clin Drug Investig. 2013 Aug;33(8):553-61. doi: 10.1007/s40261-013-0094-9.
5
. . . and losartan was no better than placebo.
J Hum Hypertens. 1999 Oct;13(10):649-50. doi: 10.1038/sj.jhh.1000926.
6
Effects of telmisartan and losartan treatments on bone turnover markers in patients with newly diagnosed stage I hypertension.
J Renin Angiotensin Aldosterone Syst. 2019 Jul-Sep;20(3):1470320319862741. doi: 10.1177/1470320319862741.
7
Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study.
J Hum Hypertens. 2003 Aug;17(8):569-75. doi: 10.1038/sj.jhh.1001592.
8
Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications.
Blood Press. 2002;11(5):302-9. doi: 10.1080/080370502320779511.
9
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Hypertens Res. 2015 Oct;38(10):690-4. doi: 10.1038/hr.2015.57. Epub 2015 May 21.
10
Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study.
J Indian Med Assoc. 2003 May;101(5):327-8.
引用本文的文献
1
Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection.
Int J Mol Sci. 2025 Aug 8;26(16):7663. doi: 10.3390/ijms26167663.
2
Therapeutic strategies to reverse cigarette smoke-induced ion channel and mucociliary dysfunction in COPD airway epithelial cells.
Am J Physiol Lung Cell Mol Physiol. 2025 Apr 1;328(4):L571-L585. doi: 10.1152/ajplung.00258.2024. Epub 2025 Mar 17.
3
Population Pharmacokinetics of Telmisartan in Healthy Subjects and Hypertensive Patients.
Clin Pharmacokinet. 2025 Feb;64(2):285-295. doi: 10.1007/s40262-024-01471-3. Epub 2025 Jan 14.
4
Structural Features Influencing the Bioactive Conformation of Angiotensin II and Angiotensin A: Relationship between Receptor Desensitization, Addiction, and the Blood-Brain Barrier.
Int J Mol Sci. 2024 May 26;25(11):5779. doi: 10.3390/ijms25115779.
5
Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients.
Heliyon. 2023 Aug 22;9(9):e19373. doi: 10.1016/j.heliyon.2023.e19373. eCollection 2023 Sep.
本文引用的文献
1
Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity.
Rev Port Cardiol. 2023 Apr;42(4):373-383. doi: 10.1016/j.repc.2022.02.014. Epub 2023 Mar 7.
2
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.
BMJ. 2022 Nov 16;379:e072175. doi: 10.1136/bmj-2022-072175.
3
Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs.
Cell Discov. 2022 Sep 9;8(1):91. doi: 10.1038/s41421-022-00454-7.
4
Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?
Eur Respir J. 2022 Dec 1;60(6). doi: 10.1183/13993003.01521-2022. Print 2022 Dec.
5
Renin-Angiotensin-System Inhibitors Are Associated With Lower In-hospital Mortality in COVID-19 Patients Aged 80 and Older.
Front Cardiovasc Med. 2022 Jun 17;9:916509. doi: 10.3389/fcvm.2022.916509. eCollection 2022.
6
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.
Curr Hypertens Rep. 2022 Oct;24(10):425-433. doi: 10.1007/s11906-022-01207-3. Epub 2022 Jun 18.
7
Effects of Angiotensin II Receptor Blockers on the Risk of Mortality in Patients with COVID-19: An Updated Systematic Review and Meta-analysis of Randomized Trials.
Am J Hypertens. 2022 Aug 1;35(8):763-764. doi: 10.1093/ajh/hpac070.
8
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial.
JAMA Netw Open. 2022 Mar 1;5(3):e222735. doi: 10.1001/jamanetworkopen.2022.2735.
9
Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease.
Clin Kidney J. 2021 Dec 14;15(3):397-406. doi: 10.1093/ckj/sfab272. eCollection 2022 Mar.
10
Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
Drugs. 2022 Jan;82(1):43-54. doi: 10.1007/s40265-021-01639-2. Epub 2021 Dec 16.
Zotero 插件